Farallon Capital Management LLC Decreases Stock Position in Ultragenyx Pharmaceutical Inc. $RARE

Farallon Capital Management LLC cut its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 99.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 7,000 shares of the biopharmaceutical company’s stock after selling 891,000 shares during the quarter. Farallon Capital Management LLC’s holdings in Ultragenyx Pharmaceutical were worth $211,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Ultragenyx Pharmaceutical by 14.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 232,360 shares of the biopharmaceutical company’s stock valued at $8,414,000 after acquiring an additional 29,984 shares during the last quarter. Envestnet Asset Management Inc. lifted its holdings in shares of Ultragenyx Pharmaceutical by 6.0% in the 2nd quarter. Envestnet Asset Management Inc. now owns 29,956 shares of the biopharmaceutical company’s stock worth $1,089,000 after acquiring an additional 1,698 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in shares of Ultragenyx Pharmaceutical by 7.0% in the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 6,783 shares of the biopharmaceutical company’s stock worth $247,000 after acquiring an additional 441 shares during the last quarter. Campbell & CO Investment Adviser LLC purchased a new position in shares of Ultragenyx Pharmaceutical during the 2nd quarter worth about $309,000. Finally, Geode Capital Management LLC grew its holdings in Ultragenyx Pharmaceutical by 4.0% during the 2nd quarter. Geode Capital Management LLC now owns 1,712,931 shares of the biopharmaceutical company’s stock valued at $62,291,000 after purchasing an additional 66,394 shares during the last quarter. 97.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on RARE shares. Wells Fargo & Company reduced their price objective on shares of Ultragenyx Pharmaceutical from $65.00 to $45.00 and set an “overweight” rating on the stock in a research report on Tuesday, December 30th. Guggenheim dropped their target price on Ultragenyx Pharmaceutical from $64.00 to $52.00 and set a “buy” rating for the company in a research report on Monday, January 5th. Bank of America cut their target price on Ultragenyx Pharmaceutical from $72.00 to $58.00 and set a “buy” rating on the stock in a research note on Friday, January 2nd. Canaccord Genuity Group reduced their price target on Ultragenyx Pharmaceutical from $128.00 to $79.00 and set a “buy” rating on the stock in a report on Wednesday, February 18th. Finally, JPMorgan Chase & Co. decreased their price target on Ultragenyx Pharmaceutical from $120.00 to $74.00 and set an “overweight” rating for the company in a research note on Thursday. Sixteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $65.76.

Ultragenyx Pharmaceutical Price Performance

RARE stock opened at $21.34 on Monday. Ultragenyx Pharmaceutical Inc. has a 12 month low of $18.41 and a 12 month high of $42.37. The firm’s 50-day moving average is $23.01 and its 200 day moving average is $28.81. The company has a market capitalization of $2.06 billion, a PE ratio of -3.65 and a beta of 0.16.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported ($1.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.20) by ($0.09). The company had revenue of $207.28 million during the quarter, compared to analysts’ expectations of $199.60 million. Ultragenyx Pharmaceutical had a negative net margin of 85.54% and a negative return on equity of 1,024.42%. Ultragenyx Pharmaceutical’s quarterly revenue was up 25.5% on a year-over-year basis. During the same period last year, the firm earned ($1.39) earnings per share. Sell-side analysts forecast that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Insider Activity

In related news, CEO Emil D. Kakkis sold 54,404 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $22.80, for a total value of $1,240,411.20. Following the completion of the sale, the chief executive officer owned 658,994 shares in the company, valued at approximately $15,025,063.20. The trade was a 7.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Theodore Alan Huizenga sold 1,632 shares of the stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $22.80, for a total value of $37,209.60. Following the completion of the transaction, the chief accounting officer directly owned 48,670 shares in the company, valued at approximately $1,109,676. This trade represents a 3.24% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 104,958 shares of company stock valued at $2,394,858. Insiders own 5.50% of the company’s stock.

Key Stories Impacting Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Phase‑3 win for DTX301 (OTC deficiency): Ultragenyx reported that its AAV8 gene therapy (DTX301) reduced ammonia ~18% versus placebo and maintained normal ammonia through 36 weeks in a late‑stage trial—an important efficacy readout that advances the program toward potential regulatory/commercial milestones. Read More.
• Neutral Sentiment: JPMorgan cuts price target but keeps an Overweight rating: JPMorgan lowered its target from $120 to $74 while maintaining an Overweight stance—reducing near‑term upside expectations but still signaling conviction in the company’s longer‑term potential relative to peers. Read More.
• Negative Sentiment: Multiple securities‑fraud class action notices and lead‑plaintiff deadlines: Several law firms and investor‑alert services (Schall, Robbins Geller, Faruqi, Rosen, Pomerantz, DJS, ClaimsFiler, etc.) have announced a securities class action covering purchases from Aug 3, 2023–Dec 26, 2025 and are soliciting lead‑plaintiff candidates (April 6, 2026 deadline). This increases legal and headline risk, can pressure the stock near term, and may create potential future liabilities. Read More.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.